INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in adults and currently represents the fourth leading cause of death in the world 1 . It has become a major and growing health problem, with a mortality rate that continues to increase. It is the only leading cause of death showing increases in prevalence worldwide and it is expected that by the year 2020, COPD will become the third leading cause of death and the number one cause of disability in adults 2 .
Chronic obstructive pulmonary disease is primarily characterized by the presence of airflow limitation that responds poorly to bronchodilators. The limitation to airflow results from airway inflammation and remodeling and/or parenchymal destruction (emphysema), which frequently coexist 3, 4 . However, there is a body of data that associate COPD to systemic manifestations that can effectively signal an increased risk for mortality [5] [6] [7] . Recognizing these manifestations provides a more comprehensive assessment of disease severity and can improve disease prognosis. This monograph reviews the following concepts and how they relate to COPD: -Definition of disease severity and staging.
-Development of BODE as an index to define COPD severity and staging.
-Use of BODE to monitor COPD progression and response to therapy.
-Conclusions.
DEFINITION OF DISEASE SEVERITY AND STAGING
There is no agreement about the definition of disease severity or staging, but some information can be used to develop the appropriate framework. Two characteristics should define the specific severity of a disease and have to be present to provide a valid classification for a specific disease. First, the variables used to quantitate severity should reflect the likelihood of death, and second and importantly, they should reflect organ compromise or failure resulting from disease progression, independent of the treatment process. In this regard, the severity of COPD should not only define the outcome of the person as a whole (all-cause mortality), but also relate to the failure of the organ (in the case of COPD, respiratory mortality, hospitalizations from COPD, or disability from the disease). For example, age is certainly associated with a poor outcome (older people are
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Bartolome R. Celli: Value of the BODE Index in COPD more likely to die than younger ones), but may not relate to failure of the lung itself. In this regard, comorbidities will certainly impact on mortality and poor health status, but may not relate to the severity of the organ compromise. Thus, a system designed to classify COPD severity should fulfill the principles outlined above.
On the other hand, staging reflects a period or phase in the course of a disease, a concept that introduces the inclusion of time and progression. Thus the variable or variables used to stage a disease should be able to change over time. The "stage" of a disease is used not only to reflect severity, but also to plan therapy or resources investment. For COPD, severity and staging are usually associated and very difficult to separate. The inclusion of variables that cannot change over time should not be part of a disease staging system; such is the case of age or gender.
THE BODE INDEX TO DEFINE CHRONIC OBSTRUCTIVE PULMONARY DISEASE SEVERITY AND STAGING
Several clinical or laboratory outcomes have been identified as individual predictors of organ dysfunction disability and/or mortality in COPD (Fig. 1) . These include the forced expiratory volume in one second (FEV 1 ) [8] [9] [10] , airways hyper-responsiveness 8, 11 , severity of dyspnea 12 , gas exchange disturbances 13 , lung hyperinflation 14, 15 , pulmonary hypertension 16 , malnutrition 17 , impaired exercise capacity [18] [19] [20] , health-related quality of life 20 , and anemia 21, 22 . As mentioned previously, age and the presence of other comorbidities also add to the global prognosis of patients with COPD, but are not by definition expressions of the disease process in the lung itself and therefore I shall not use them to define disease severity 23, 24 . In this monograph, we will review these individual variables as predictors of mortality, hospitalizations for COPD, and disability. We will also discuss the power of BODE as an integrated, multidimensional tool to more broadly characterize COPD severity and assess response to therapeutic intervention as well.
Predictors of outcome in chronic obstructive pulmonary disease and development and validation of BODE The initial step in the development of a multidimensional index should be to study the potential variables that could relate to the outcomes, as mentioned before. Table 1 shows a list of the variables that a review of the literature at the time the BODE cohort was assembled suggested a relationship with poor outcomes. From these, we selected those with the strongest support from the literature 25 . These included variables related to lung function, such as forced vital capacity (FVC), FEV 1 , functional residual capacity (FRC), and inspiratory capacity (IC) and arterial blood gases (PaO 2 and PaCO 2 ). Dyspnea was evaluated with the Modified Medical Research Council (MMRC) scale. As an expression of the impact of the disease on functional capacity, we selected the six-minute walk distance (6MWD), and for nutritional status the body mass index (BMI). We also evaluated albumin and hemoglobin as well as smoking intensity, with pack/ years as they had been associated with COPD. Finally, we also included age and the Charlson comorbidity score to evaluate whether the index to be developed was independent of these factors. The first 207 patients recruited were followed for one year and 25 of them died.
There were differences between survivors and non-survivors in all of the variables evaluated except in the pack years, FRC, and albumin. However, the significance of the difference varied for the different tests, being strongest for the FEV 1 percentage of predicted, the MMRC dyspnea scale, the 6MWD, and BMI. Based on this, on the fact that these variables measured different domains and in addition were independently associated with all-cause and respiratory mortality, we decided to include them in the creation of the index (Fig. 2) . Neither age nor comorbidities were included in this process because they are independent predictors of mortality, but not of respiratory mortality or COPD disability. In addition, the variables selected are relatively easy to measure and can respond to therapy or change over time.
The acronym BODE was derived from the initials of each of the components (BMI, 25 . However, a study of a larger cohort by Puhan, et al. 26 observed a better predictive value when more weight was assigned to the 6MWD.
Once the index was developed, it was tested and followed prospectively every 3-6 months for two years or until death in a cohort of 625 patients with COPD in five centers located in three countries (USA, Spain, and Venezuela).
The BODE index predicted all-cause mortality with a 30% increase in risk of death per each unit increase in BODE index. Not only was all-cause mortality predicted, but more importantly, the association of the BODE index was even stronger with mortality from respiratory causes (HR: 1.62; 95% CI: 1.48-1.77; p < 0.001), supporting the premise needed to develop a COPD severity system.
BODE as a chronic obstructive pulmonary disease prognostic and staging tool
Following its initial publication, many reports have tested the prognostic value of BODE for several outcomes. The first was the study by Ong, et al. 27 who recruited 127 patients with COPD and determined their BODE index. The patients were followed for up to two years and the number of hospital admissions and mortality were documented. The investigators found the median BODE score to be lower among survivors than among non-survivors (4 vs. 6, respectively; p = 0.003) and a significant effect of the BODE scores on mortality (HR: 1.30; 95% CI: 1.08-1.56; p = 0.006). The investigators used Poisson regression analysis to evaluate the effect of BODE scores on hospitalizations and found BODE to also be a predictor of this outcome. Exacerbations and hospitalizations were also predicted by BODE in a study that included the expanded original cohort followed over five years. In a study of 275 patients followed for an average of eight years, Marin, et al. 28 showed that the mean time to a first COPD emergency room visit was 6.7, 3.6, 2.0, and 0.8 years for each BODE quartiles (all p < 0.05). Using ROC curves, the BODE index was a better predictor of exacerbation than FEV 1 alone (p < 0.01). More recently, there are indices that incorporate the number or type of comorbidities based on the observation that multi-morbidity is a frequent occurrence in patients with COPD. The CODEX index incorporated comorbidities (measured by Charlson), degree of airflow obstruction, dyspnea, and previous severe exacerbations in over 900 patients 40 .
The index predicted all-cause mortality better than the BODEx or ADO indices after hospital discharge. A few studies have attempted to compare several of these indices across a larger spectrum of patients. The COPD collaborative cohorts to assess multicomponent indices (COCOMIC) group in Spain collected data from several cohorts consisting in total of over 3,000 patients followed for up to 10 years 41 . In this analysis with all-cause mortality as the outcome, the BODE and its modifications (m-BODE, BODEx) had similar properties once adjusted for age.
The Global Initiative for Obstructive Lung Disease also developed a grading system, but Bartolome R. Celli: Value of the BODE Index in COPD did it without validation 4 . The system includes FEV 1 , dyspnea or health status, and exacerbations. Then, using absolute thresholds, the patients are placed in one of four grades: A, B, C and D. In the only study where the ABCD grading system was compared with the BODE, De Torres, et al. 42 added the COTE comorbidity index to BODE, and in this study the C statistic for mortality offered the highest value reported of 0.81 (95% CI: 0.77-0.86). This was significantly better than the ABCD or BODE alone. BODE on its own (C statistic 0.63) was better than the ABCD (C statistic 0.54), (p < 0.001).
Taken together, all of these studies have confirmed that multidimensional indices are better than individual variables to predict mortality and in the case of BODE, exacerbations and hospitalizations as well as respiratory mortality.
However, all of the studies cited lack a crucial element; none has been tested to see if their implementation improves clinical outcomes. Some authors recommend stopping creating more indices, but rather to plan and complete studies designed to test whether incorporating the use of any index in the clinic improves care of patients with COPD. In a series of reviews aimed at helping guide the development of prognostic indices, Moons, et al. clearly state that it is best to calibrate already developed indices rather than to continue to develop new ones 43 .
BODE to monitor chronic obstructive pulmonary disease progression
The concept that BODE reflects disease progression has been explored in several studies. Cote, et al. assessed the impact of exacerbations on BODE and its components 44 . In this study that lasted two years, 205 patients were recruited and evaluated with the BODE index at baseline while stable, then during the exacerbation event and every six months thereafter. A total of 130 patients experienced exacerbations and 75 patients remained exacerbation-free for the duration of the study. Exacerbators showed a worsening of BODE index of 1.38 points during the exacerbation, and although there was a partial improvement, the BODE index at 24 months remained 1.09 points above baseline. On the contrary, non-exacerbators showed a negligible increase in BODE at two years (0.07 points), which differed significantly from that of the exacerbators (p < 0.001). Casanova, et al. used a different approach 45 . They compared the prognostic validity of longitudinally followed FEV 1 and BODE in a study of over 700 patients over five years. The change in BODE index over time had less variability than the changes and variability of the FEV 1 . It also was a better predictor of mortality than any of the individual variables that integrate the BODE. In a different report from patients in the same cohort, Sanchez-Salcedo, et al. compared the progression of COPD in younger (< 55 years) and older (> 65 years) patients 46 . BODE progressed similarly in both age groups, indicating that BODE can be used independent of age, as has been also observed in women 47 . All of these results support the concept that BODE can be used to define COPD progression and, more importantly, provide evidence that it can be used to stage the disease as it changes with time.
BODE to monitor response to therapy
The first evaluation of BODE as a surrogate marker of response to therapy was completed by Imfeld, et al. in a clinical study of 186 patients with severe emphysema 48 . They tested the predictive value of BODE following lung volume reduction surgery (LVRS) and found that the post-operative BODE, but not pre-operative BODE, predicted survival. The LVRS resulted in improvement in BODE from 7.2 (quartile 4), to 4.0 (quartile 2) (p < 0.001). Those patients having the most improvement in BODE had the best five-year survival (HR: 0.497; 95% CI: 0.375-0.659; p < 0.001). The investigators found that the BODE index was able to predict the risk of death (ROC, AUC: 0.74), better than the FEV 1 (ROC, AUC: 0.63). Martinez, et al. in the NETT study randomized over 1000 patients with inhomogeneous emphysema to either LVRS or medical treatment 32 . The LVRS resulted in significant improvement in the BODE index compared with patients randomized to the medical arm. Importantly, a decrease of one unit of BODE at six months predicted survival at 1, 2, and 5 years after randomizations, whereas an increase in one unit was associated with decreased survival.
Pulmonary rehabilitation (PR) is known to improve several of the surrogate markers for mortality in COPD, namely dyspnea, health status, and exercise capacity. Based on this observation, it was hypothesized that PR would modify the stage of COPD and the risk for mortality as measured by the BODE index 49 . In this study, of the 246 patients who qualified for and were offered rehabilitation, 116 accepted and completed the eight-week, three-times weekly rehabilitation program; 130 declined participation. The changes in BODE scores were compared between rehabilitated patients and non-PR participants. The patients had severe COPD both by FEV 1 and by BODE. Patients were followed for more than two years or until death. Approximately 30% of the patients who graduated from PR joined a maintenance program and exercised three-times weekly for the entire two-year period. Following PR, 71% of the participating patients improved their BODE index scores by at least one point; of these 25% improved by two points. After graduation from PR, the BODE index decreased significantly from 5.07 to 4.18. This resulted in a "shift" from the third quartile to the second quartile, and their initially predicted mortality of 20-30% changed to an observed mortality of 11.2%. Patients who declined PR had a worse BODE index at entry of 6.94 (approaching BODE fourth quartile), and in this group there was almost a 20% worsening of BODE index over time. This group of patients had the highest mortality rate (50%). For patients who responded to PR, defined as an improvement in the BODE index score of at least one point, BODE index scores improved by a statistically significant 25% at three months, compared with the patients who did not respond to rehabilitation. These improvements in BODE index scores were maintained for a full two years after the start of PR, while patients who did not participate in PR displayed an 18% deterioration in BODE index scores. Bu, et al., in Australia, enrolled 56 patients with COPD in an observational study, following them for two years 50 . A total of 33 patients worsened their BODE, in 18 the BODE remained unchanged, and it improved in five. Patients whose BODE index increased had more exacerbations, hospitalizations, and longer hospital stay.
Taken together, the response of patients to exacerbations, LVRS, and PR can be captured by the BODE index, not only reflecting changes on disease severity, but also a marker of outcome, suggesting that the BODE index can be used as both surrogate marker for mortality, a staging tool, and also a tool to assess disease modification.
CONCLUSIONS
The severity of a disease is determined using variables that are associated with likelihood of death and, second and importantly, they should reflect organ compromise or failure resulting from disease progression. Simple to use, the validated multi-dimensional BODE index predicts survival, respiratory death, and organ failure better than its individual components. The BODE index captures the multiple pulmonary and systemic manifestations of COPD, and is proving to be a valuable tool not only in the assessment of severity and progression of disease, but also in evaluating the response to therapeutic interventions. More studies are needed to determine the value of BODE in clinical practice.
